| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/19/2004 | US20040033951 Modified mature insulin variants and composition containing same |
| 02/19/2004 | US20040033946 Cell damage inhibitor |
| 02/19/2004 | US20040033945 Pharmaceutical compositions for treating asthenia or anaemia or for making a food supplement |
| 02/19/2004 | US20040033936 Reduced or "leuco" forms produced and/or stabilised by mixing the unreduced compounds or the reduced compounds, respectively, with acid and a sulphydryl compound, especially a sulphur-containing amino acid, or peptide or derivative |
| 02/19/2004 | US20040033563 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 02/19/2004 | US20040033511 Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines) |
| 02/19/2004 | US20040033491 Proteins and nucleic acids encoding same |
| 02/19/2004 | US20040033258 Compression molded blend of a basic medicinal component having an unpleasant taste, a saccharide, a polyanionic polymer, a corrigent, and carboxymethylcellulose; quickly disintegrating in the oral cavity. |
| 02/19/2004 | US20040033256 Long-acting insulin formulation that may be aerosolized for pulmonary administration. |
| 02/19/2004 | US20040033216 Harvesting the pancreas of piglets at or near full term gestation, and extracting pancreatic beta islet cells exposed to nicotinamide |
| 02/19/2004 | US20040033202 Nanoparticulate sterol formulations and novel sterol combinations |
| 02/19/2004 | DE10237379A1 Production of formic acid-formate e.g. preservative and animal feed additive, comprises partial hydrolysis of methyl formate, separation of formic acid, base hydrolysis of remaining ester and combination with formic acid |
| 02/19/2004 | DE10217555A1 Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix Physiologically acceptable, phospholipid-containing, stable and hard matrix |
| 02/19/2004 | CA2496002A1 Albumin-fused ciliary neurotrophic factor |
| 02/19/2004 | CA2495518A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | CA2495516A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | CA2495502A1 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | CA2495419A1 Remedy |
| 02/19/2004 | CA2494942A1 Substituted benzimidazole compounds |
| 02/19/2004 | CA2494916A1 Medicinal composition for lowering blood lipid level |
| 02/19/2004 | CA2494865A1 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | CA2494827A1 Cannabinoid receptor ligands |
| 02/19/2004 | CA2494785A1 Dihydropyrazolopyridine compounds |
| 02/19/2004 | CA2494298A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| 02/19/2004 | CA2494269A1 Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide |
| 02/19/2004 | CA2494026A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | CA2493660A1 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | CA2493491A1 Process for selective production of aryl 5-thio-.beta.-d-aldohexopyranosides |
| 02/19/2004 | CA2493143A1 2,3-dihydro-isoindol-1-ones with mao-b inhibiting activity |
| 02/19/2004 | CA2492940A1 Novel difluorinated gem compounds, preparation methods thereof and applications of same |
| 02/19/2004 | CA2478889A1 Aryl 5-thio-.beta.-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same |
| 02/18/2004 | EP1389621A1 N-substituted pyrazolyl-o-glycoside derivatives and remedial agent for diabetes containing the same |
| 02/18/2004 | EP1389619A1 Pkb-3564 substance with neovascularization inhibitory activity |
| 02/18/2004 | EP1389618A1 Pyrazolo 1,5-a]pyridines and medicines containing the same |
| 02/18/2004 | EP1389611A1 20-hydroxyeicosatetraenoic acid production inhibitors |
| 02/18/2004 | EP1389466A1 Immunopotentiators |
| 02/18/2004 | EP1389464A1 Compositions containing bacterium capable of converting lactic acid into butyric acid and method of preventing/treating hyperlactic acidemia in digestive tract and colon cancer by using the same |
| 02/18/2004 | EP1389233A1 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/18/2004 | EP1389206A2 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 02/18/2004 | EP1389205A1 Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders |
| 02/18/2004 | EP1389204A1 Novel sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same |
| 02/18/2004 | EP1389202A1 2,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonists |
| 02/18/2004 | EP1389189A2 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
| 02/18/2004 | EP1389137A2 Compositions for protein delivery via the pulmonary route |
| 02/18/2004 | EP1389130A2 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 02/18/2004 | EP1389124A1 Palliative effects of morinda citrifolia oil and juice |
| 02/18/2004 | EP1389118A1 Single-daily-dose antidiabetic oral pharmaceutical form comprising a biguanide and at least another active principle |
| 02/18/2004 | EP1389112A2 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders |
| 02/18/2004 | EP1389110A2 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 02/18/2004 | EP1389105A1 Method of treatment |
| 02/18/2004 | EP1389103A2 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents |
| 02/18/2004 | EP1292572B1 Propanolaminotetralines, preparation thereof and compositions containing same |
| 02/18/2004 | EP1233786B1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance for the preparation of a medicament |
| 02/18/2004 | EP1183252B1 pharmaceutically active compounds |
| 02/18/2004 | EP1178958B1 N-cyanomethyl amides as protease inhibitors |
| 02/18/2004 | EP1171416B1 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors |
| 02/18/2004 | EP1143988B1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases |
| 02/18/2004 | EP1133494B1 8-azabicyclo 3.2.1]oct-2-ene and -octane derivatives |
| 02/18/2004 | EP1133477B1 Substituted benzimidazoles and their use as parp inhibitors |
| 02/18/2004 | EP1131089B1 Stable aqueous insulin preparations without phenol and cresol |
| 02/18/2004 | EP1123314B1 Use of a cytokine-producing lactococcus strain to treat colitis |
| 02/18/2004 | EP1119568B1 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| 02/18/2004 | EP1049691B1 Substituted 5-(2,2-difluoro-1,3-benzodioxol-5-yl) cyclopentenopyridine derivative |
| 02/18/2004 | EP1014968B1 NARINGIN AND NARINGENIN AS 3-HYDROXY-3-METHYLGLUTARYL CoA(HMG-CoA) REDUCTASE INHIBITOR |
| 02/18/2004 | EP0983270B1 Process for preparing 6-o-monoesters of castanospermine |
| 02/18/2004 | EP0941110B1 Uses of keratinocyte growth factor-2 |
| 02/18/2004 | EP0865294B1 Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
| 02/18/2004 | CN1476448A Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 02/18/2004 | CN1476447A Aminothiazoles and their use as adenosine receptor antagonists |
| 02/18/2004 | CN1476445A 4-(bipheny/carbony/amino) piperidine derivatives as MTP inhibitors |
| 02/18/2004 | CN1476440A Lactonization process |
| 02/18/2004 | CN1476439A Salts of aiso thiazole-4-carboxamide and their use as anti-hyperproliferatin agents |
| 02/18/2004 | CN1476438A Fused heteroaromatic glucokinase activators |
| 02/18/2004 | CN1476432A Indole and dihydroindole derivatives |
| 02/18/2004 | CN1476333A Composition for diminishing neutral fat blood |
| 02/18/2004 | CN1475491A Aminoglucose diphosphate and its synthesis method and preparation of medicine for treating stomash disease using said salt |
| 02/18/2004 | CN1475488A Fluoro isoflavone containing derivative, monufacturing method and its use |
| 02/18/2004 | CN1475487A Fluoro flavon containing compound, manufacturing method and its use |
| 02/18/2004 | CN1475249A Fatty acid synthetic enzyme inhibitor and its production method and application |
| 02/18/2004 | CN1475224A Compound preparation of levocarnitin and adenosine triphosphate |
| 02/18/2004 | CN1475222A Vine leaf extract and its preparation process |
| 02/18/2004 | CN1475218A Medicinal preparation composed of diphosphate and aminoglucose salt and its use |
| 02/18/2004 | CN1475213A Soyisoflavone soft capsule and its preparation technology |
| 02/18/2004 | CN1475212A Compound preparation of levocarnitine and calcium pantothenate |
| 02/18/2004 | CN1475211A Compound preparation of levocarnitine and coenzyme Q10 |
| 02/18/2004 | CN1475209A Slow-released agent form of sertraline |
| 02/18/2004 | CN1475208A Slow-released agent form of sertraline |
| 02/18/2004 | CN1475207A Solid oral dosage mode containing walshaden and hydrochloric thizaine |
| 02/18/2004 | CN1475206A Medical composition containing micropowdery bicyclic medicine |
| 02/18/2004 | CN1138786C Antibody for identifying osteoclast forming inhibitor binding protein, and preparing process and use |
| 02/18/2004 | CN1138774C Substituted 6,6-hetero-bicyclic derivatives |
| 02/18/2004 | CN1138771C 6-hydroxy-3-(4-[2-piperidine-1-group) oxyethyl group] phenoxy)-2-(4-methoxyphenyl) benzo[b] thiophene hydrochloride salt |
| 02/18/2004 | CN1138770C 6-carbonyl-3-(4-[2-pierid-1-yl)elhoyl]phenoxy)-2-(4-methoxylphenyl) benzo[b] thiophene salt crystal |
| 02/18/2004 | CN1138760C Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 02/18/2004 | CN1138550C Process of producing extracts of shark |
| 02/18/2004 | CN1138546C Certain 1,4,5-tri-substituted imidazole compounds useful as cytokine |
| 02/18/2004 | CN1138537C Probucol clathrate capsule and its prepn. process |
| 02/18/2004 | CN1138472C Dipeptide apoptosis inhibitors and use thereof |
| 02/17/2004 | US6693192 Hypolipidemic and antioxidant morpholine derivatives |
| 02/17/2004 | US6693165 Cyclic peptides as potent and selective melanocortin-4 receptor antagonists |